PyInvesting

Market research

603387.SHG Getein Biotech, Inc

SHG CNY Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
5B
P/E ratio
20.48
Analyst target
37.4
Dividend yield
2.5%
Beta
-0.05

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Getein Biotech, Inc is currently in a long term downtrend where the price is trading 33.8% below its 200 day moving average.

From a valuation standpoint, the stock is 16.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.0.

Getein Biotech, Inc's total revenue rose by 13.4% to $383M since the same quarter in the previous year.

Its net income has dropped by 28.1% to $101M since the same quarter in the previous year.

Finally, its free cash flow fell by 28.9% to $72M since the same quarter in the previous year.

Based on the above factors, Getein Biotech, Inc gets an overall score of 2/5.